Wire · regulatory
FDA-SEC MOU Could Heighten Scrutiny Of Drugmaker Investor Disclosures
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 2 September 2026 · Fusion42 review
The FDA and SEC have formed an information-sharing agreement that could increase regulatory scrutiny of pharmaceutical and biotechnology companies' investor disclosures, particularly concerning clinical trial data and regulatory approvals.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face new pressure as the FDA sharing information with the SEC adds a layer of scrutiny to your public disclosures. This raises the stakes on how transparently and accurately you report trial and approval news to investors.
◆ Coverage
1 source · 1 Sep 2026
◆ Related on Wire
◆ Topics
BiotechFDA-SEC-mouinvestor-disclosuresdrugmakersregulatory-scrutinyclinical-trials